A detailed history of Pacer Advisors, Inc. transactions in Exact Sciences Corp stock. As of the latest transaction made, Pacer Advisors, Inc. holds 708 shares of EXAS stock, worth $29,913. This represents 0.0% of its overall portfolio holdings.

Number of Shares
708
Holding current value
$29,913
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$56.27 - $73.77 $39,839 - $52,229
708 New
708 $48,000
Q1 2022

Apr 05, 2022

SELL
$57.56 - $82.54 $46,220 - $66,279
-803 Closed
0 $0
Q4 2021

Feb 03, 2022

BUY
$72.5 - $100.68 $58,217 - $80,846
803 New
803 $62,000
Q3 2021

Oct 15, 2021

SELL
$90.24 - $124.05 $81,125 - $111,520
-899 Closed
0 $0
Q2 2021

Jul 21, 2021

BUY
$93.66 - $139.27 $27,629 - $41,084
295 Added 48.84%
899 $112,000
Q1 2021

Apr 05, 2021

SELL
$116.57 - $155.01 $48,376 - $64,329
-415 Reduced 40.73%
604 $80,000
Q4 2020

Jan 20, 2021

SELL
$99.61 - $142.12 $20,918 - $29,845
-210 Reduced 17.09%
1,019 $135,000
Q3 2020

Oct 19, 2020

BUY
$72.92 - $102.01 $89,618 - $125,370
1,229 New
1,229 $125,000
Q4 2018

Feb 13, 2019

SELL
$56.04 - $82.66 $233,742 - $344,774
-4,171 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$48.29 - $80.6 $201,417 - $336,182
4,171 New
4,171 $329,000
Q1 2018

May 14, 2018

SELL
$39.82 - $57.53 $104,527 - $151,016
-2,625 Closed
0 $0
Q4 2017

Feb 14, 2018

SELL
$46.49 - $60.51 $771,036 - $1 Million
-16,585 Reduced 86.34%
2,625 $138,000
Q3 2017

Nov 08, 2017

BUY
$37.05 - $47.12 $711,730 - $905,175
19,210
19,210 $905,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $7.48B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Pacer Advisors, Inc. Portfolio

Follow Pacer Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pacer Advisors, Inc. with notifications on news.